7 July 2026 - The US FDA has approved Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.

The efficacy and safety of Trutakna were evaluated in a randomized, double-blind, placebo-controlled clinical trial in adults with biopsy-confirmed IgA nephropathy. Patients were randomly assigned to either Trutakna 150 mg injected subcutaneously once weekly or placebo.

Read FDA press release